CagriSema
ALSO SOLD AS Cagrilintide + semaglutide
See the stack breakdown →Last reviewed 2026-10-30
Our read Opinion
REDEFINE 1 provides phase 3 randomized evidence of weight reduction. The investigational cagrilintide component makes the combination prohibited under WADA S0.
- Type
- Investigational (in trials)
- Regulatory status
- Investigational combination; not FDA-approved
- Compounding status
- Not allowed (blends excluded)
- FDA-approved indications
- None
- Evidence level
- Human trials ongoing
- Routes studied
- —
- WADA
- Prohibited
- Developer
- Novo Nordisk
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Claimed to produce more weight loss than semaglutide alone
Combines amylin-receptor agonism from cagrilintide with GLP-1 receptor agonism from semaglutide to reduce appetite and food intake.
Not a peptide: a pre-mixed blend of cagrilintide and semaglutide, developed by Novo Nordisk as an investigational combination product. Semaglutide approval does not confer approval on CagriSema; no combination marketing authorization was verified.
Statuses change; check the linked primary source.
Momentum Opinion
Watch
0 news items in last 30 days
Phase 3 evidence makes this more than a speculative stack, but it remains a distinct investigational product. Unregulated mixtures should not borrow the credibility of sponsor-controlled trials.
No news yet for this peptide.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.